PharmLabs

PharmLabs PharmLabs is a full-service analytical lab specializing in peptides, cannabis, hemp-derived products, and botanicals.

We provide testing for cannabinoids, mushrooms, and natural compounds to ensure safety, quality, and compliance. PharmLabs provides the cannabis community with lab testing and analytical services for Compliance Testing and Quality Assurance purposes.

🧪 QUESTION OF THE WEEK 🧪When evaluating peptide, cannabinoid, mushroom, kratom, or h**p products, what matters more…📊 Po...
06/03/2026

🧪 QUESTION OF THE WEEK 🧪

When evaluating peptide, cannabinoid, mushroom, kratom, or h**p products, what matters more…

📊 Potency Testing or🔬Purity & Contaminant Testing?

For years, potency has been one of the most talked-about metrics in the industry. Higher cannabinoid concentrations, stronger mushroom products, and more potent formulations often drive purchasing decisions.

But potency only tells part of the story.

A product can have impressive potency results while still containing unwanted contaminants such as heavy metals, pesticides, residual solvents, or other impurities that impact quality, safety, and consumer trust.

As testing standards continue to evolve across the h**p, cannabinoid, peptide, kratom, and psychedelic markets, many industry professionals are asking an important question:
Should potency remain the primary metric consumers focus on, or is it time for purity and contaminant screening to take center stage?

👇 We want to hear from you.
If you could only review ONE laboratory result before purchasing a product, would you choose?

Share your answer and reasoning in the comments. We’ll feature some of the most insightful responses in next week’s discussion.

At PharmLabs, we believe transparency starts with comprehensive testing. From potency and identity verification to heavy metals, pesticides, residual solvents, and contaminant screening, our mission is to help brands and consumers make informed decisions backed by science.

Follow for weekly industry discussions, testing insights, regulatory updates, and educational content.

🚨 This Weeks Industry News: Minnesota is becoming one of the latest states to explore regulated psychedelic-assisted the...
05/26/2026

🚨 This Weeks Industry News:

Minnesota is becoming one of the latest states to explore regulated psychedelic-assisted therapy programs. Lawmakers recently approved legislation directing the Minnesota Office of Cannabis Management to study and submit recommendations for a future psilocybin pilot program, potentially setting the stage for broader therapeutic access in 2027.

The original proposal included a supervised therapeutic pilot program for adults 21+ experiencing qualifying conditions such as:
• PTSD
• Major depression
• Substance use disorder
• Chronic mental health conditions

While the final legislation was scaled back into a research and reporting initiative, industry analysts view this as another major signal that psychedelic policy reform continues gaining traction across the United States.

Minnesota now joins a growing list of states actively exploring regulated psychedelic therapies alongside Oregon, Colorado, and New Mexico.

🥼 Why this matters for the industry:
Psychedelic-assisted therapies are increasingly being discussed within broader conversations surrounding:
• mental health innovation
• neuroplasticity research
• trauma recovery
• addiction treatment
• emerging biotech and pharmaceutical development

Several lawmakers and veterans testified that supervised psilocybin treatment helped address treatment-resistant PTSD and depression, contributing to bipartisan momentum behind the legislation.
At the federal level, interest in psychedelic research has also accelerated in 2026, with growing discussions surrounding therapeutic frameworks, clinical trials, and potential FDA pathways.

Read full article here
https://www.cbsnews.com/minnesota/news/minnesota-magic-mushroom-pilot-program-study/

PharmLabs is committed to supporting the future of regulated wellness through trusted analytical testing, quality assurance, and industry compliance solutions.
Contact PharmLabs today for a free quote.
📧 [email protected]
🌐 www.sdpharmlabs.com
☎️ 619-356-0898
📱 DM us directly for collaborations and inquiries

Not all compounds remain stable after collection. 🧪MYTH OR FACT: Psychedelics like DMT and psilocybin mushrooms remain c...
05/21/2026

Not all compounds remain stable after collection. 🧪

MYTH OR FACT: Psychedelics like DMT and psilocybin mushrooms remain chemically stable in samples without specialized storage?

✅ MYTH.

Compounds such as DMT and psilocybin are highly sensitive to environmental factors including heat, oxygen, light exposure, and improper storage. Over time, degradation can occur potentially impacting potency, analytical accuracy, product consistency, and overall testing reliability.

This is why proper sample handling, validated analytical methods, and professional laboratory testing play a critical role in ensuring accurate potency verification, contaminant screening, and regulatory compliance.

At PharmLabs, we provide advanced analytical testing for psychedelics, h**p-derived products, cannabinoids, peptides, kratom, amanita muscaria and more helping brands and consumers make data-driven decisions backed by science.

💬 Have questions about potency testing, stability, or compliance? Drop them in the comments or send us a DM.

Question of the Week ⁉️If federal h**p laws tighten in 2026…
should Delta-8 and THCA products be fully restricted or str...
05/19/2026

Question of the Week ⁉️

If federal h**p laws tighten in 2026…
should Delta-8 and THCA products be fully restricted or strictly regulated instead?

The h**p industry is facing increasing pressure as regulators revisit how intoxicating h**p-derived cannabinoids are defined and controlled.

At the center of the debate, should these products be removed from the market entirely, or brought under stricter, standardized regulation?

This decision could reshape:
• product availability
• compliance requirements
• testing standards
• COA expectations
• how brands formulate and sell products

As regulations evolve, accurate third-party testing becomes even more critical for both compliance and consumer trust.

💬 Where do you stand?
Fully restrict or strictly regulate?
Drop your thoughts in the comments.

**pIndustry

Congress is moving toward tightening federal h**p regulations, with proposed changes shifting focus from Delta-9 THC lim...
05/19/2026

Congress is moving toward tightening federal h**p regulations, with proposed changes shifting focus from Delta-9 THC limits to total THC and THCA conversion standards.

If passed, many h**p-derived THC products (including Delta-8 and THCA flower) could face new compliance challenges, requiring reformulation, retesting, or removal from the market.

For brands, this means one thing: testing and compliance are becoming more important than ever.

Accurate lab data is now critical for:
• Potency verification
• Regulatory compliance
• COA accuracy
• Retailer approval

Read full article here: https://www.marijuanamoment.net/house-passes-farm-bill-including-h**p-provisions-but-without-delaying-thc-product-ban-scheduled-for-this-year

At Pharmlabs, we help brands stay ahead of changing regulations with reliable cannabinoid and compliance testing.

📩 Contact us to get your products tested or request a COA review.

**p

Selling h**p products in Texas? Your COAs and compliance testing matter more than ever.PharmLabs now offers Texas-compli...
05/12/2026

Selling h**p products in Texas? Your COAs and compliance testing matter more than ever.

PharmLabs now offers Texas-compliant h**p testing services designed to help manufacturers meet all requirements under 25 TAC §300 Consumable H**p Program regulations.

If your products are sold in Texas, they must:
✔️ Be tested before sale
✔️ Meet legal THC limits (≤0.3% Delta-9 THC)
✔️ Include a batch-specific COA
✔️ Provide a QR code or URL linked to the COA on the label

PharmLabs delivers complete compliance solutions for:
🌿 H**p Brands
🏭 Manufacturers
🛒 Retail Products
📦 Distributors entering the Texas market

Our accredited testing panels include:
• Cannabinoid Potency + Total THC
• Residual Solvents
• Heavy Metals
• Pesticides
• Microbial Contaminants

What sets PharmLabs apart:
🔬 ISO/IEC 17025 Accredited
🇺🇸 Fast Domestic Turnaround, No Customs Delays
📲 QR-Ready COAs Built for Texas Label Compliance
📈 Consistent, Defensible Results Trusted by Brands Nationwide
🧪 Advanced Expertise in H**p & Cannabinoid Science

Don’t let compliance issues stop your products from reaching shelves. PharmLabs helps ensure your products are tested, compliant, and retail-ready from day one.

Partner with PharmLabs for professional h**p compliance testing today.
📞 (619) 356-0898
📧 [email protected]
🌐 www.sdpharmlabs.com

**pIndustry

🧠 MYTH OR FACT?
Psychedelics like psilocybin and L*D act only on serotonin receptors in the brain?Answer: MYTH.While it ...
05/06/2026

🧠 MYTH OR FACT?
Psychedelics like psilocybin and L*D act only on serotonin receptors in the brain?

Answer: MYTH.

While it is true that classic psychedelics primarily interact with the 5-HT2A serotonin receptor, modern neuroscience shows the story is far more complex.

These compounds also influence:
• Glutamate signaling pathways
• Large-scale brain network connectivity
• Neuroplasticity (the brain’s ability to reorganize and form new connections)
• Downstream effects tied to cognition, emotion, and perception

This means psychedelics are not acting on a single “switch” in the brain, they are modulating entire neural systems, which is why research interest has expanded into areas like depression, PTSD, and treatment-resistant mental health conditions.

As the science evolves, rigorous analytical testing and compound characterization become critical to ensure consistency, purity, and research validity.

🔬 At PharmLabs, we support innovation in emerging psychoactive and novel compounds with advanced analytical testing services designed for accuracy, compliance, and scientific integrity.

📩 Explore how PharmLabs can support your research, formulation, or compliance testing needs.

Request a free quote for testing services today.
🌐 www.sdpharmlabs.com
📧 [email protected]
📞 (619) 356-0898

Question Of The Week! Things are moving quickly right now in the testing space.We’re seeing continued growth and momentu...
05/06/2026

Question Of The Week!

Things are moving quickly right now in the testing space.

We’re seeing continued growth and momentum across cannabinoids, psychedelics, peptides, and novel compounds, with each category presenting its own unique analytical challenges, regulatory considerations, and opportunities for innovation.

As the industry evolves, so does the need for accurate, consistent, and reliable data.
From your perspective, where do you see the most significant growth coming from next?

Which category do you think will drive the next wave of testing demands? Cannabinoids, Psychedelics, Peptides, or Novel Compounds?

Take a guess and share your perspective below, we want to hear from you!

Looking for reliable analytical testing?
At PharmLabs, we provide accurate, compliant, and defensible testing across a wide range of sample types including cannabinoids, psychedelics, peptides, and novel compounds.

Request a free quote for testing services today.
🌐 www.sdpharmlabs.com
📧 [email protected]
📞 (619) 356-0898

🚨 Industry News: The regulatory landscape for psychedelics is entering a new phase.On April 18, 2026, a federal executiv...
05/05/2026

🚨 Industry News: The regulatory landscape for psychedelics is entering a new phase.

On April 18, 2026, a federal executive order directed the U.S. Food and Drug Administration to accelerate the review of psychedelic-based therapies, including compounds such as psilocybin, M**A, and ibogaine, for the treatment of conditions such as PTSD and depression.

While these substances remain federally controlled, the order signals a clear shift toward expanded clinical research and faster regulatory pathways for potential medical use.

Read full article here https://www.theguardian.com/us-news/2026/apr/18/trump-psychedelic-drugs-executive-order

As these therapies move closer to regulated pharmaceutical frameworks, the importance of analytical rigor becomes increasingly critical.

Consistency in potency, verification of purity, and comprehensive contaminant screening are not optional, they are essential requirements for safety, compliance, and clinical credibility.

At PharmLabs, we recognize that as innovation accelerates, so does the demand for validated, defensible data. In emerging therapeutic markets, trust is built through precision, transparency, and standardized testing.

Progress in this space will be defined by the quality of the science behind it.

Address

6696 Mesa Ridge Road Ste A
San Diego, CA
92110

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

(619) 356-0898

Alerts

Be the first to know and let us send you an email when PharmLabs posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to PharmLabs:

Featured

Share